Carcinoid Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Carcinoid syndrome (CS) is a
paraneoplastic syndrome caused by the discharge of serotonin and different
substances from well-differentiated neuroendocrine tumors (NETs). CS is a paraneoplastic
syndrome associated with the secretion of around 40 vasoactive hormones, the
majority of which are 5-hydroxytryptamine (5-HT). CS also involves the
secretion of histamine (primary gastric NETs), prostaglandins E and F,
kallikrein, and tachykinins. The hallmark symptoms of carcinoid syndrome are
diarrhea and flushing; atypical signs and symptoms can include wheezing,
pellagra, valvular heart disease, telangiectasias, abdominal pain, and the
complications of mesenteric fibrosis, including ureteral obstruction, bowel
ischemia, and bowel obstruction. These symptoms are mediated by the release of
serotonin (5-HT), prostaglandins, kallikrein, histamine, and tachykinins. These
symptoms, as well as the corresponding elevations in lab tests, are required for
the diagnosis of CS. Surgery and medical management are options for treatment,
with somatostatin analogs representing the cornerstone of therapy.
·
The incidence of carcinoid syndrome is 0.27
per 100,000 in the United States.
Thelansis’s “Carcinoid Syndrome (CS)
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Carcinoid
Syndrome (CS) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Carcinoid Syndrome (CS) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Carcinoid Syndrome (CS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment